Taylor Morrison Home
TMHC
Meritage Homes
MTH
D.R. Horton
DHI
Lennar Corp
LEN
Toll Brothers
TOL
US Stock MarketDetailed Quotes
VRTX Vertex Pharmaceuticals
- 480.350
- -1.300-0.27%
Close Feb 25 16:00 ET
- 479.560
- -0.790-0.16%
Pre 04:05 ET
123.35BMarket Cap-230.94P/E (TTM)
486.140High476.260Low1.20MVolume480.950Open481.650Pre Close576.64MTurnover0.47%Turnover RatioLossP/E (Static)256.79MShares519.88052wk High7.52P/B122.92BFloat Cap377.85052wk Low--Dividend TTM255.89MShs Float519.880Historical High--Div YieldTTM2.05%Amplitude7.250Historical Low480.708Avg Price1Lot Size
About Vertex Pharmaceuticals Company
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Company Profile
SymbolVRTX
Company NameVertex Pharmaceuticals
Listing DateJul 4, 1991
Issue Price13.75
Founded1989
CEODr. Reshma Kewalramani, M.D.
MarketNASDAQ
Employees6100
Fiscal Year Ends12-31
Address50 Northern Avenue
CityBoston
ProvinceMassachusetts
CountryUnited States of America
Zip Code02210
Phone1-617-341-6100
Websitehttp://www.vrtx.com
Company Executives
- Name
- Position
- Salary
- Dr. Reshma Kewalramani, M.D.
- Director, President and Chief Executive Officer
- 20.59M
- Dr. Ourania Tatsis, PhD
- Executive Vice President and Chief Regulatory and Quality Officer
- --
- Dr. David Altshuler
- Executive Vice President and Chief Scientific Officer
- 6.54M
- Carmen Bozic
- Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer
- --
- Charles F. Wagner, Jr
- Executive Vice President and Chief Financial Officer
- 7.37M
- Dr. E Morrow Atkinson, III, PhD
- Executive Vice President, Chief Technical Operations Officer and Head, Biopharmaceutical Science and Manufacturing Operations
- --
- Jonathan Biller
- Executive Vice President and Chief Legal Officer
- --
- Stuart A. Arbuckle
- Executive Vice President and Chief Operating Officer
- 9.00M
- Kristen Ambrose
- Senior Vice President and Chief Accounting Officer
- --
- Amit K. Sachdev, J.D.
- Executive Vice President and Chief Patient and External Affairs Officer
- --
- Duncan J. McKechnie
- Senior Vice President and Head, North America Commercial Team
- --
- Dr. Jeffrey M Leiden, PhD
- Executive Chairman of the Board
- 6.60M
- Suketu Upadhyay
- Independent Director
- 544.66K
- Dr. Sangeeta N. Bhatia, PhD
- Independent Director
- 550.31K
- Nancy A. Thornberry
- Independent Director
- 407.65K
- Diana L. McKenzie
- Independent Director
- 553.11K
- Lloyd A. Carney
- Independent Director
- 559.79K
- Dr. Jennifer Schneider, M.D.
- Independent Director
- --
- Dr. Alan M. Garber, M.D.,PhD
- Independent Director
- 537.63K
- Michel Lagarde
- Independent Director
- 449.08K
- Bruce I. Sachs
- Lead Independent Director
- 600.04K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
